Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.58 USD
-0.12 (-7.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.60 +0.02 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Gain Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
GANX 1.58 -0.12(-7.06%)
Will GANX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 9th
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GANX
GANX Fell Below 50 Day Moving Average on September 19
GANX Crossed Above 50 Day Moving Average on September 19
GANX forms Directional Movement Crossover Bearish on September 17
Gain Therapeutics (GANX) Extends Phase 1b Study for Parkinson's Treatment
Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s